National Guideline Clearinghouse | Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis.

full-text ►

National Guideline Clearinghouse | Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis.



National Institute for Health and Care Excellence (NICE)

January 27, 2014

Guideline Title

Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Jun. 61 p. (Technology appraisal guidance; no. 289).

Guideline Status

This is the current release of the guideline.